Sanofi Drops Dupixent Successor Candidate After Assessing Data
Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety data, ending plans for regulatory filings.
Sanofi stopped developing a new skin-medicine candidate because test results weren't good enough. When a medicine project gets dropped, watch how much the company might lose from that missed opportunity.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.